门静脉灌注化疗治疗肝癌伴门静脉瘤栓的临床价值  

Clinical value of portal vein chemotherapy in treatment of hepatocellular carcinoma with tumor thrombosis of main trunk of portal vein

作　　者：李强[1] 郝希山[1] 张忠国[1] 宋天强[1] 郝继辉[1] 马维东[1] 孙涛[1] 王殿昌[1] 

机构地区：[1]天津医科大学附属肿瘤医院,天津市300600

出　　处：《中华肝胆外科杂志》2002年第7期420-421,共2页Chinese Journal of Hepatobiliary Surgery

摘　　要：目的　探讨肝细胞肝癌伴门脉癌栓 (tumorthrombiinportalvein ,PVTT)外科手术后 ,门静脉灌注化疗的价值。方法　 4 5例伴门脉主干或Ⅰ级分支癌栓的肝癌病人 ,在行手术切除后随机分组 ,一组行肝动脉化疗 ,同时行门静脉灌注化疗 (治疗组 ) ,另一组仅行肝动脉化疗 (对照组 )。结果　治疗组 6 ,12 ,18个月生存率分别为 85 1% ,76 5 %和 4 7 2 %。对照组为 73 3% ,5 9 2 %和 33 4 % ,两组比较差异均有显著性 (P <0 0 5 )。结论　肝癌伴PVTT ,手术切除术后 ,为防治门脉癌栓导致肝内转移复发 ,术中除应尽量取净癌栓组织外 。Objective To investigate the value of portal vein chemotherapy (PVC) for hepatocellular carcinoma (HCC) with portal vein tumor thrombi (PVTT). Methods Forty five HCC patients with tumor thrombi in the main portal vein or its first branch received surgical resection. All the 45 patients were divided into the treated group (n=21) and the control group (n=24). The patients in the treated group received infusion through the liver artery and portal vein while those in the control group received it through the liver artery alone. Results The 6 , 12 and 18 month survival rates were 85.1%, 76.5% and 47.2% in the treated group and 73.3%, 59.2% and 33.4% in the control, respectively. There was significant difference between the two groups. Conclusions Hepatectomy for HCC with removal of tumor thrombi and transcatheter hepatic arterial and portal vein infusion is an effective treatment for HCC with PVTT.

关 键 词：门静脉灌注化疗 治疗 肝癌 门静脉瘤栓 临床价值 

分 类 号：R735.7[医药卫生—肿瘤] R730.53[医药卫生—临床医学]